In the quest to enhance the efficacy of chimeric antigen receptor T (CAR-T) cell therapy against hepatocellular carcinoma (HCC), a recent study has identified a pivotal role for CD39 expression in ...

Carisma Therapeutics (CARM) announced the upcoming presentation of new pre-clinical data on its anti-GPC3 in vivo chimeric antigen receptor ...

In the quest to enhance the efficacy of chimeric antigen receptor T (CAR-T) cell therapy against hepatocellular carcinoma (HCC), a study in Frontiers of Medicine has identified a pivotal role for CD39 ...

Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the ...

Surveillance programs for chronic hepatitis B, which also include a focus on treatment, can be beneficial for patients.

A new immune cell biomarker has been discovered that can predict the effectiveness of immune anticancer treatment in patients ...

Hepatocellular carcinoma (HCC) is the most common type of liver cancer and ranks among the leading causes of cancer-related deaths globally. Traditional treatment methods, including surgical resection ...

TriSalus Life Sciences (NASDAQ:TLSI – Get Free Report) is one of 236 public companies in the “Surgical & medical instruments” industry, but how does it compare to its rivals? We will compare TriSalus ...

Liver cancer is the sixth leading cause of cancer death in the U.S. The most common type of liver cancer in adults is ...

Find Infections Prevention Latest News, Videos & Pictures on Infections Prevention and see latest updates, news, information ...

Namodenoson is an oral drug with a proven favorable safety profileRAMAT GAN, Israel, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd.